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Abstract
We have developed an emulsion-solvent evaporation method for producing
haloperidol loaded PLGA nanoparticles with up to 2 % (wt/wt. of polymer) drug content,
in-vitro release duration of over 13 days and less than 20% burst release. The free
haloperidol is removed from the nanoparticle suspension using a novel solid phase
extraction technique. This leads to a more accurate determination of drug incorporation
efficiency than the typical washing methods. We have discovered that PLGA end groups
have a strong influence on haloperidol incorporation efficiency and its release from
PLGA nanoparticles. The hydroxyl terminated PLGA (uncapped) nanoparticles have a
drug incorporation efficiency of more than 30% as compared to only 10% with methyl
terminated PLGA (capped) nanoparticles. The in-vitro release profile of nanoparticles
with uncapped PLGA has a longer release period and a lower initial burst as compared to
capped PLGA. By varying other processing and materials parameters, we also controlled
the size, haloperidol incorporation and haloperidol release of our haloperidol loaded
PLGA nanoparticles.
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Introduction
Biodegradable microparticles and nanoparticles are promising candidates for
controlled drug delivery and can deliver small molecular weight drugs, peptides or genes
to the tissue of interest. The therapeutic agent of interest is encapsulated within the
polymer matrix of biodegradable particles to achieve extended release (Allemann et al.,
1996; Soppimath and Aminabhavi, 2002). The drug is released slowly over an extended
time interval; the polymer degrades and is metabolized by the body. The polymers used
most extensively for long-term drug delivery are poly(lactic acid) (PLA), poly(glycolic
acid) (PGA) and their copolymer poly(lactide-co-glycolide acid) (PLGA) (Jain et al.,
1998).
Nanoparticles have been successfully used for systemic, oral, pulmonary and
transdermal routes for various purposes (M J Cappel, 1991). A nanoparticulate drug
delivery system, once designed, can be evaluated on the basis of four important
performance metrics. These are: particle size, drug incorporation efficiency, drug content
and the drug release characteristics. Hence a basic understanding of all the factors
controlling the above mentioned performance metrics is of paramount importance in
designing a nanoparticulate drug delivery system for a particular drug.
Haloperidol is an extensively used, highly potent antipsychotic drug.

An

uninterrupted supply of antipsychotic medication therapy is vital for patient health. A
long-term drug delivery system would be an ideal candidate to improve drug adherence
and to ensure a continuous supply of optimum dosage levels of the drug. The aim of our
research is to understand the various factors that affect the crucial performance metrics of
haloperidol-loaded nanoparticles including- size, drug incorporation, loading and release.
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We have produced haloperidol-loaded PLGA nanoparticles using an emulsificationsolvent evaporation method and have developed a novel solid phase extraction technique
to remove the non-encapsulated haloperidol (free haloperidol) from the formulation.
Subsequent to production, the particles were extensively studied for factors influencing
haloperidol incorporation, particle size and haloperidol release from the particles. We
have determined that the PLGA end groups, the haloperidol-PLGA interaction and the
PLGA hydrophobicity most strongly influence the haloperidol incorporation and its
release from nanoparticles.

Materials and Methods
Materials
Poly (D,L-lactic-co-glycolic acid) (PLGA) 50:50 DL 3A (inherent viscosity, 0.37
dL/g), 50:50 DL 3M (inherent viscosity, 0.36 dL/g), 95:5 (inherent viscosity, 0.68 dL/g)
were purchased from Alkermes, USA. Polyvinyl alcohol (PVA) (MW, 25,000, 88%
hydrolyzed) was purchased from Polysciences Inc., USA. Haloperidol, PBS, ammonium
acetate, HEPES were purchased from Sigma, USA. Acetonitrile, DCM and acetone were
purchased from Fisher scientific. All the solvents were HPLC grade.

Nanoparticle preparation
An emulsification-solvent evaporation method was used to prepare haloperidol
loaded PLGA nanoparticles. Haloperidol and 100 mg of PLGA was dissolved in 3 ml of
DCM. 50 ml of surfactant solution (250 mg of PVA dissolved in 50 ml of pH 10 HEPES
buffer) was added to the organic phase and an O/W emulsion was prepared by
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homogenizing at 12000 rpm for 7 minutes (Kinematica Polytron Benchtop Homogenizer,
Brinkmann Instruments).

The nanodroplets were then stirred at 400 rpm under

atmospheric conditions for 2-3 hours to evaporate the DCM and form polymer
nanoparticles. Unless otherwise noted, the following set of parameters was chosen to
prepare the nanoparticles: PLGA 50:50 uncapped, molecular weight 51 kD at a
concentration of 33.3 mg/ml in DCM; initial haloperidol concentration of 0.83 mg/ml in
DCM; aqueous phase of pH 10; PVA as surfactant at a concentration of 1% wt/vol.;
homogenization at 12000 rpm for 7 minutes.

Free drug extraction
This method consists of passing the nanoparticulate suspension through a
cartridge packed with porous particles of a polymeric sorbent that selectively captures
basic analytes, while allowing the nanoparticles (with encapsulated drug) to pass through
as effluent. The sorbent captures haloperidol, a basic drug, through a combined reversedphase and mixed-cation-exchange chromatographic mechanisms. Specifically, our
nanoparticulate suspensions were passed through Oasis Mixed-Cation-Exchange (MCX)
cartridges (Waters, USA) pre-conditioned with methanol and water to solvate the sorbent.
The effluent nanoparticle suspension was taken for drug incorporation studies and invitro release studies.

Nanoparticle characterization
The size and size distribution of the nanoparticles were measured by laser
dynamic light scattering. (DLS, 90 plus Particle Size Analyzer, Brookhaven Instruments,
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USA). Scanning electron microscopy (SEM, JEOL 6300F FEG HRSEM, USA; 5 kV)
was used to determine the shape and surface texture of the nanoparticles. One ml of the
nanoparticulate suspension was dried under vacuum, coated with platinum in a sputter
coater (Cressington 108 Sputter Coater) and examined by SEM.
The haloperidol content and incorporation efficiency were measured using HPLC
(Waters, USA) with a reversed phase Symmetry C18 5.0 micrometer column (4.6mm x
150mm). The mobile phase used for the column was 38 % acetonitrile and 62 % 10mM,
pH 4.8 ammonium acetate solution. After being passed through the MCX cartridge, a 1ml of nanoparticulate suspension was dissolved in 40 ml of mobile phase and a 50 µl
aliquot of this sample was injected in HPLC machine with an auto injector (Waters
717plus Autosampler). The column effluent was detected at 254 nm by UV
spectrophotometry (Waters 2487 Dual wavelength absorbance detector). A calibration
curve for haloperidol was obtained using a series of haloperidol standards prepared in the
mobile phase. The calibration curve was linear in the range of concentrations measured.
The encapsulation efficiency was obtained as the ratio of the amount of haloperidol
incorporated in the nanoparticles to the total amount of haloperidol used. Drug content
was calculated as the ratio of the mass of drug inside the nanoparticles to the total initial
mass amount of the polymer. Since the polymer recovery was close to 90%, this method
of drug content calculation gave similar results as the usual method of taking it as the
ratio of the drug amount inside the particles to the total mass recovered. Thus, this
method of calculating drug content provides a lower limit of drug content and the true
drug content could be ~10%-12% higher.
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In-vitro release study
The in-vitro release study of the haloperidol-loaded PLGA nanoparticles was
carried out in stirred dissolution cells at 37.4°C by suspending the nanoparticulate
suspension in large quantity of pH 7.4 PBS solution such that the total amount of
haloperidol inside the suspended nanoparticles is less than 10% of its solubility limit in
PBS buffer. This ensures the correct in-vitro conditions to study the release behavior of a
hydrophobic drug (Chorny et al., 2002b).

One ml aliquots were taken out of the

dissolution cells at pre-determined time intervals, replaced by fresh PBS buffer and
analyzed for released haloperidol.

Results and Discussion
A novel method to eliminate free drug and determine drug incorporation
We compared the haloperidol incorporation in PLGA nanoparticles determined
after using the standard method of multiple washings and our method of solid phase
extraction.

Two batches of haloperidol loaded nanoparticle suspensions were each

divided into three groups: (i) Raw nanoparticle suspension, (ii) Washed nanoparticle
suspension, and (iii) Stripped nanoparticle suspension. The Raw nanoparticle suspension
refers to the nanoparticulate suspension obtained just after solvent evaporation. The
Washed nanoparticle suspensions refer to raw nanoparticles that were centrifuged and
washed thrice with distilled water. The Stripped nanoparticle suspensions refer to the
raw suspension passed through MCX cartridges.
Table 1 shows the % haloperidol in the nanoparticle suspension (Raw, Washed
and Stripped) for two initial concentrations of haloperidol. The raw suspension has a
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relatively large amount of haloperidol, ~90%, because it contains both free and
encapsulated haloperidol. The Washed suspension has a lower value of % haloperidol,
~70%, indicating that some of the free drug is indeed removed by the washing method.
The Stripped suspension has the lowest value, < 40%, owing to the complete removal of
free drug.
These data suggest that the nanoparticle suspension prepared using the
emulsification solvent-evaporation method contains some drug that is encapsulated
within the polymer nanoparticles while the remaining drug is suspended outside the
particles or sticks loosely on the particle surfaces. Thus the incomplete removal of free
drug by washing techniques leads to an overestimation of the drug incorporation
efficiency and drug content inside the particles.
Some researchers have addressed the problem of incomplete free drug removal by
proposing alternative techniques of free drug removal from the nanoparticulate
suspension(Baichello et al., 1999), (Aberturas et al., 2002). These methods are either
cumbersome or they require an exact knowledge of the solubility behavior of the drug in
the aqueous phase, in the presence of the surfactant. Alternatively, our method of solid
phase extraction is a simple and efficient method to remove the free drug completely
from the nanoparticulate suspension.

Size and size distribution
The mean nanoparticle size and size distribution is affected by the organic
solvent, polymer concentration and processing parameters. SEM images indicate that the
nanoparticles are spherical in shape, and thus will be described by an effective diameter
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and a size polydispersity obtained by DLS (Figure 1).

For the same polymer

concentration of 33.3 mg/ml PLGA, the effective diameter for particles prepared with
acetone is 275 ± 25 nm while it is 524 ± 220 nm for particles prepared with DCM (Figure
1 a, c). The particles obtained from acetone have a unimodal population distribution with
a polydispersity of 0.04 (Figure 1a). With DCM, the particles have a bimodal population
distribution and, consequently, a high polydispersity of ~ 0.29 (Figure 1c). Decreasing
the PLGA concentration in DCM from 33.3 mg/ml to 20 mg/ml changes the particle size
distribution from bimodal to unimodal (Figure 1 c, b). Figure 2 shows that the effective
particle diameters for a range of PLGA concentration in both acetone and DCM.
Bimodal distributions of particles were obtained with DCM at higher polymer
concentrations while acetone gives unimodal distributions of particles at all polymer
concentrations. The diameters of the two populations obtained from DCM are shown by
dotted lines while the mean diameter is shown by full line.
The polymer concentration and organic solvent selection are critical in producing
unimodal nanoparticles. DCM, a water immiscible solvent, forms nanoparticles by a true
emulsification mechanism in which the larger emulsion droplets are broken into smaller
droplets by the application of external energy (Bodmeier and Mcginity, 1987). At higher
polymer concentrations, the energy applied through homogenization is insufficient to
overcome the resistive viscous forces provided by the dissolved PLGA in the organic
phase and the dissolved surfactant (PVA) in the aqueous phase, leading to heterogeneous
droplets and a bimodal size distribution.
In contrast, acetone, a water-soluble solvent, gives a smaller sized, more uniform,
unimodal population even in the absence of homogenization through a nanoprecipitation
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mechanism (Chorny et al., 2002a; Fessi et al., 1989; Quintanar-Guerrero et al., 1998).
Acetone rapidly diffuses into the aqueous phase resulting in the precipitation of the
polymer (PLGA) that forms nanoparticles. Thus, the preparation of nanoparticles using
acetone is less sensitive to the polymer concentration and the homogenization parameters
than when using DCM. Birnbaum et. al. (Birnbaum et al., 2000a) have reported similar
trends with DCM and acetone for their PLGA nanoparticles.

Drug incorporation efficiency and drug content
Effect of initial haloperidol concentration. Figure

3a

shows

the

haloperidol

incorporation efficiency values for various initial concentrations of PLGA 50:50 (33.3
mg/ml, 25 mg/ml and 16.6 mg/ml) in DCM. There are two trends evident in Figure 3a.
First, the haloperidol incorporation efficiency decreases upon increasing the initial
haloperidol concentration for a fixed initial polymer concentration. Second, for a fixed
initial drug concentration, the haloperidol incorporation efficiency increases upon
increasing the initial PLGA concentration. However, the haloperidol content in the
nanoparticles has a constant value of ~1 % for PLGA 50:50 particles, irrespective of the
initial polymer or drug concentrations for the range tested (Figure 3b). Similar trend was
observed for capped PLGA 95:5 particles (data not shown).
The initial drug to polymer ratio in the organic phase is critical in determining the
drug incorporation, although the larger values of this ratio lead to smaller values of drug
incorporation.

This unexpected finding is furthered by the observation that the

haloperidol content in the nanoparticles is independent of the initial haloperidol
concentration. These results combine to suggest that the final haloperidol content in
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these PLGA nanoparticles has an upper limit, which cannot be increased by simply
increasing the initial haloperidol to polymer ratio in the emulsion. Rather increasing the
initial haloperidol to polymer ratio in the emulsion leads to an increase in the amount of
free drug, while the amount of encapsulated drug remains constant. Chorny et. al.
(Chorny et al., 2002b) also reported an upper limit on their drug (tyrphostin AG-1295)
amount that can be incorporated in a fixed amount of PLGA. Barichello et. al. (Baichello
et al., 1999) suggested that a low affinity between PLGA and their drug (valproic acid)
may be responsible for extremely low incorporation efficiency of 5.6 %. Hence, the
physical encapsulation of haloperidol in PLGA is limited by the haloperidol-PLGA
interaction.

Effect of PLGA end groups. We found that the end groups have a significant effect on
the haloperidol incorporation and its release behavior from the nanoparticles. Two types
of PLGA polymers were used to produce haloperidol-loaded nanoparticles: uncapped
(carboxyl acid end group) and capped (methyl ester end group) PLGA (Figure 4). The
haloperidol incorporation efficiency with uncapped PLGA 50:50 is 32 ± 15 %, which is
three times higher than with capped PLGA 50:50, 8 ± 5 %. Also, the haloperidol
incorporation values for capped PLGA 50:50 (~8%) and capped PLGA 95:5 (~12%) are
comparable, thus indicating that the L:G ratio is less important than the endgroups. The
importance of endgroups has previously been suggested for PLGA microspheres loaded
with the drugs gentamicin (Nagata S, 1994) and leuprorelin (Takada S, 1998). There is
also a report for PLGA nanoparticles in which the end group doubles the protein loading
(Gaspar M M, 1998).
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Based on these results, we propose that the presence of carboxylic acid groups (COOH) increases the hydrogen bonding between the PLGA chains and the haloperidol
molecules, which hinders the drug diffusion out of the polymer nanoparticle during
solvent evaporation. Thus the amount of haloperidol incorporated in the uncapped PLGA
matrix is higher due to the tendency for hydrogen bonding between –COOH end groups
and haloperidol (Figure 4b). The -COCH3 end group of capped PLGA and the –CH2OH
end group of both capped and uncapped PLGA are much less capable of forming a
hydrogen bond with haloperidol. This is further verified if we consider two nanoparticles
samples: uncapped and capped PLGA nanoparticles, prepared with 2.5 mg of haloperidol
and 100 mg of polymer of molecular weight ~50 kD corresponding to ~1.2*1018–COOH
end groups in the uncapped PLGA. If each –COOH group corresponds to one additional
haloperidol molecule (by virtue of hydrogen bonding) then the uncapped PLGA
nanoparticles would contain ~0.75 mg more haloperidol than the capped PLGA
nanoparticles. The initial haloperidol amount was 2.5 mg, so this corresponds to an
increase of ~30% in haloperidol incorporation, which is comparable to the observed
increase of ~24%.

Hence the polymer end groups exercise significant effect on

haloperidol incorporation and content in the nanoparticles.

In-vitro release study
The release rate is strongly influenced by the PLGA end groups and the PLGA
copolymer composition (L:G ratio). Figure 5 shows the cumulative % of haloperidol
released as a function of time for nanoparticles made from PLGA 50:50, uncapped and
capped. It can be seen that the particles from uncapped PLGA have a lower initial burst
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of ~40% as compared to that of ~70% from capped PLGA.

Also, ~95% of the

haloperidol is released in 4 days from uncapped PLGA nanoparticles while it takes only 2
days with capped PLGA.
There are two opposing factors that contribute to the drug release from PLGA
nanoparticles. The rate of hydrolysis is higher for uncapped PLGA, corresponding to a
faster release. Conversely, the strength of haloperidol-PLGA interactions is greater for
the uncapped PLGA due to the –COOH groups, yielding slower drug release. In our
haloperidol-PLGA nanoparticles, the slower release observed in uncapped PLGA 50:50
(relative to capped 50:50) indicates that the haloperidol-PLGA interactions dominate the
release profile.

The prolonged drug release from our nanoparticles prepared using

uncapped PLGA is consistent with the extended release response reported for
nanospheres of L-asparginase and PLGA.(Gaspar M M, 1998)

In contrast other

researchers have reported faster drug release when using uncapped PLGA.(Soppimath
and Aminabhavi, 2002) (Lam X M, 2000). These opposing observations can be
reconciled by considering the balance between the rate of polymer hydrolysis and the
strength of drug-polymer interactions for specific drug-polymer combinations. In our
haloperidol-PLGA system and the L-asparginase-PLGA system (Gaspar M M, 1998)
there are strong interactions between the drug molecules and the carboxylic acid end
groups of the uncapped PLGA chains. This is evident from the fact that the drug
incorporation in uncapped vs. capped PLGA nanoparticles increases by thrice and twice,
respectively, in the above two systems. These strong interactions clearly overwhelm the
faster hydrolysis typical of uncapped PLGA causing an overall slower release for
uncapped PLGA. On the other hand, the rhIGF-I-PLGA system (Lam X M, 2000) and the
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nifedipine-PLGA system (Soppimath and Aminabhavi, 2002) have the same drug
incorporation for uncapped and capped PLGA indicating the absence of any favorable
interaction between the drug and polymer end groups. So in these cases the faster
hydrolysis of the uncapped PLGA dominates and the overall release is faster for the
uncapped PLGA particles. Clearly, the balance between faster hydrolysis and stronger
interactions is specific to the number and type of drug-PLGA interactions and thus will
be drug dependent.
In addition to the influence of end groups, the PLGA composition strongly
influences release. Figure 6a shows the cumulative % haloperidol release for
nanoparticles made from capped PLGA 95:5 and uncapped PLGA 50:50 as a function of
time. Both sets of particles have a drug content of ~0.3% and a bimodal size distribution
with populations of ~250 nm and ~970 nm in size. It can be seen that the capped PLGA
95:5 particles exhibit low burst release of ~15% as compared to that of ~35% with
uncapped PLGA 50:50. The drug release period is ~13 days with capped PLGA 95:5 as
opposed to ~2 days with uncapped PLGA 50:50.
Another release study was performed for unimodal particles made from uncapped
PLGA 50:50 and capped PLGA 95:5 and the particle diameter was monitored. These
particles from both polymers have an initial effective diameter of ~630 nm and the drug
loading is ~1.9 % for uncapped PLGA 50:50 particles and ~0.4 % for capped PLGA 95:5
particles.

As expected, the haloperidol release is slower from capped PLGA 95:5

nanoparticles, Figure 6b. The particle size, as measured by dynamic light scattering,
remains approximately constant for both sets of particles during the in vitro release study,
Figure 6c. Comparison of drug release profiles for the same polymer in Figures 6a and
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6b suggests that the particle size, size distribution and drug loading also influence drug
release rate.
Drug can be released from polymer nanoparticles by the mechanism of diffusion
and/or polymer erosion. We have observed that haloperidol release from bulk PLGA
requires many weeks as it proceeds by both diffusion and polymer erosion (Steven J
Siegel, 2002). In contrast, the nanoparticles studied here release the haloperidol without a
detectable change in effective diameter. Thus, the mechanism governing release from
these nanoparticles is predominantly drug diffusion. Furthermore, the slower release
from capped PLGA 95:5 can be understood in terms of drug diffusion, because the
increased hydrophobicity of capped PLGA 95:5 as compared to uncapped PLGA 50:50
corresponds to less hydration and swelling and consequently slower drug diffusion out of
the polymer matrix. The dramatic differences in drug release characteristics between
bulk and nanoparticle PLGA systems highlights the importance of size when designing
materials smaller than 1 micron, as is typical in the field of nanotechnology.

Conclusions
Haloperidol-loaded PLGA particles were produced using an emulsificationsolvent evaporation method. The size of the particles can be varied from 200 nm to 2000
nm and is most strongly affected by solvent miscibility and polymer concentration in the
organic phase. Solid phase extraction was used to remove free drug from the nanoparticle
suspension. PLGA with a –COOH end group (uncapped) substantially increases the drug
incorporation in these nanoparticles, perhaps through the mechanism of hydrogen
bonding. Haloperidol incorporation in uncapped PLGA nanoparticles is three times that
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in capped PLGA nanoparticles. Including –COOH end groups on PLGA (uncapped) and
increasing the PLA content in the PLGA reduces the initial burst and extends the duration
of drug release from the nanoparticles. Uncapped PLGA shows a lower initial burst
release (~40%) and a longer period of haloperidol release (~4 days) as compared to
capped PLGA (~70% burst release and ~2 day release period). Nanoparticles prepared
from uncapped PLGA 95:5 show a lower burst release of ~15 % and have a drug release
period of ~13 days. While release in bulk mixtures of PLGA-drug is dominated by the
degradation rate of the PLGA, the drug release from PLGA-haloperidol nanoparticles is
dominated by the diffusion rate of the drug as controlled by the swelling of the PLGA,
which is related to the PLA content, and the interactions between the drug and the PLGA.
The distinctions between bulk and nanoparticle drug loaded PLGA systems highlight the
importance of size on the production and properties of materials, a cornerstone of
nanotechnology, and suggest general approach to engineering nanoparticles for extended
drug delivery.
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Tables

Table 1: Comparison of haloperidol incorporation for various preparation methods as
indicated.
Initial haloperidol

% haloperidol in the nanoparticle suspension

concentration in DCM

relative to the initial amount of haloperidol
Raw

Washed

Stripped

0.83 mg/ml

92 ± 3

70 ± 8

37 ± 6

1.67 mg/ml

90 ± 5

75 ± 3

23 ± 5
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Figure Captions
Figure 1: Nanoparticle size distribution provided by dynamic light scattering histograms
and the SEM images of nanoparticles prepared using PLGA 50:50 at (a) 33.3 mg/ml
initial concentration in acetone, (b) 20 mg/ml initial concentration in DCM, and (c) 33.3
mg/ml initial concentration in DCM. The nanoparticles in (a) and (b) are unimodal in
size while those in (c) are bimodal.
Figure 2: Effect of PLGA 50:50 concentration in the organic phase on the nanoparticle
effective diameter for particles prepared with DCM and acetone as the organic solvents.
The dotted lines indicate the diameters of the two populations in case of DCM at higher
concentrations. The full lines indicate the mean effective diameters for particles prepared
with DCM ( ) and with acetone ( ).
Figure 3: (a) Haloperidol incorporation efficiency as a function of initial haloperidol
loading for various initial concentrations in DCM of uncapped PLGA 50:50 (of MW 51
kD). (b) Final haloperidol content in the nanoparticles as a function of initial haloperidol
concentration for various initial concentrations of PLGA 50:50. Legends: : 33.3 mg/ml
of PLGA 50:50; : 25mg/ml of PLGA 50:50; S: 16.6 mg/ml of PLGA 50:50.
Figure 4: (a) Chemical structure of capped (-COCH3 terminated) PLGA. (b) Schematic
showing the hydrogen bonding between uncapped (-COOH terminated) PLGA and
haloperidol.
Figure 5: In-vitro haloperidol release from PLGA 50:50 nanoparticles for

uncapped

(-COOH terminated) and  capped (-COCH3 terminated) PLGA. Nanoparticles prepared
with uncapped PLGA exhibit a lower initial burst release and a longer release period as
compared to nanoparticles prepared with capped PLGA.

21

Figure 6: (a) In-vitro haloperidol release from PLGA nanoparticles with bimodal size
distribution. Nanoparticles prepared from capped PLGA 95:5 () show an extended
drug release period and a lower initial burst release as compared to nanoparticles
prepared from uncapped PLGA 50:50 ( ). (b) In-vitro haloperidol release profile from
PLGA nanoparticles with unimodal size distribution and prepared from uncapped PLGA
50:50 and capped PLGA 95:5.

(c) Variation of the effective diameter of the particles in

part (b) as measured by dynamic light scattering. The error bars represent the standard
deviation of the effective diameter from triplicate light scattering data.
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Figure 2:
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Figure 3
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Figure 5
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Figure 6
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